Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations

Journal of Addiction Medicine

Volumn 4, Issue 2, 2010, Pages 99-107

  Knudsen, Hannah K ^a   Roman, Paul M ^a   Oser, Carrie B ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Health services research; Medication adoption; Medication assisted treatment

Indexed keywords

EID: 77954390642     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181b41a32     Document Type: Article

References (61)

1. Carroll KM, Rounsaville BJ. Bridging the gap: A hybrid model to link efficacy and effectiveness research in substance abuse treatment. Psychiatr Serv. 2003;54:333-339.
2. L-Enfant C. Clinical research to clinical practice lost in translation? New Engl J Med. 2003;349:868-874.
3. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.
4. Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Disorders: Quality Chasm Series. Washington, DC: National Academy Press; 2006.
5. Lamb S, Greenlick MR, McCarty D. Bridging the Gap between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment. Washington, D.C.: National Academy Press; 1998.
6. Ginexi EM, Hilton TF. What-s next for translation research? Eval Health Prof. 2006;29:334-347.
7. Read JP, Kahler CW, Stevenson JF. Bridging the gap between alcoholism treatment research and practice: Identifying what works and why. Prof Psychol-Res Pr. 2001;32:227-238. (Pubitemid 33283858)
8. Simpson DD. A conceptual framework for transferring research to practice. J Subst Abuse Treat. 2002;22:171-182. (Pubitemid 34606036)
9. Sloboda Z, Schildhaus S. A discussion of the concept of technology transfer of research-based drug "abuse" prevention and treatment interventions. Subst Use Misuse. 2002;37:1079-1087. (Pubitemid 34847891)
10. Saxon AJ, McCarty D. Challenges in the adoption of new pharmaco-therapeutics for addiction to alcohol and other drugs. Pharmacol Ther. 2005;108:119-128. (Pubitemid 41377124)
11. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA. 1999;281:1318-1325. (Pubitemid 29174484)
12. Heinrich CJ, Hill CJ. Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res. 2008;43:951-970.
13. Kranzler HR. Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol Alcohol. 2000;35:537-547.
14. Ling W, Compton P. Recent advances in the treatment of opiate addiction. Clin Neurosci Res. 2005;5:161-167. (Pubitemid 41679110)
15. McGovern MP, Fox TS, Xie HY, et al. A survey of clinical practices and readiness to adopt evidence-based practices: Dissemination research in an addiction treatment system. J Subst Abuse Treat. 2004;26:305-312.
16. Cartwright WS, Solano PL. The economics of public health: Financing drug abuse treatment services. Health Policy. 2003;66:247-260. (Pubitemid 37433957)
17. Chriqui JF, Terry-McElrath Y, McBride DC, et al. State policies matter: The case of outpatient drug treatment program practices. J Subst Abuse Treat. 2008;35:13-21.
18. Heinrich CJ, Fournier E. Dimensions of publicness and performance in substance abuse treatment organizations. J Policy Anal Manage. 2004; 23:49-70.
19. Mark TL, Coffey RM, McKusick D, et al. National Estimates of Expenditures for Mental Health Services and Substance Abuse Treatment, 1991-2001. Rockville, MD: SAMHSA; 2005.
20. Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007;87:164-174.
21. Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol. 2006; 26(Suppl 1):S13-S19.
22. Knudsen HK, Ducharme LJ, Roman PM. The use of antidepressant medications in substance abuse treatment: The public-private distinction, organizational compatibility, and the environment. J Health Soc Behav. 2007;48:195-210.
23. Vocci F, Ling W. Medications development: Successes and challenges. Pharmacol Ther. 2005;108:94-108. (Pubitemid 41377122)
24. Fuller BE, Rieckmann T, McCarty D, et al. Adoption of naltrexone to treat alcohol dependence. J Subst Abuse Treat. 2005;28:273-280. (Pubitemid 40592129)
25. Mark TL, Kranzler HR, Poole VH, et al. Barriers to the use of medications to treat alcoholism. Am J Addict. 2003;12:281-294. (Pubitemid 37175521)
26. Mark TL, Kranzler HR, Song X. Understanding US addiction physicians- low rate of naltrexone prescription. Drug Alcohol Depend. 2003; 71:219-228.
27. Oser CB, Roman PM. Organizational-level predictors of adoption across time: Naltrexone in private substance-use disorders treatment centers. J Stud Alcohol Drugs. 2007;68:852-861.
28. Oser CB, Roman PM. A categorical typology of naltrexone-adopting private substance abuse treatment centers. J Subst Abuse Treat. 2008; 34:433-442.
29. Roman PM, Johnson JA. Adoption and implementation of new technologies in substance abuse treatment. J Subst Abuse Treat. 2002;22:211-218.
30. Thomas CP, Wallack SS, Lee S, et al. Research to practice: Adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat. 2003;24: 1-11. (Pubitemid 36315767)
31. Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. J Subst Abuse Treat. 2006;30:363-373.
32. Koch AL, Arfken C, Schuster CR. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 2005;83:274-278. (Pubitemid 43914266)
33. Knudsen HK, Roman PM, Ducharme LD, et al. Organizational predictors of pharmacological innovation adoption: The case of disulfiram. J Drug Issues. 2005;35:559-574.
34. Griffith JR, Sahney VK, Mohr RA. Re-Engineering Health Care: Building on CQU. Ann Arbor, MI: Health Administration Press; 1995.
35. Miller WR, Sorensen JL, Selzer JA, et al. Disseminating evidence-based practices in substance abuse treatment: A review with suggestions. J Subst Abuse Treat. 2006;31:25-39. (Pubitemid 43928414)
36. Rieckmann T, Daley M, Fuller BE, et al. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007;32:207-215. (Pubitemid 46240725)
37. McCarty D, Fuller BE, Arfken C, et al. Direct care workers in the national drug abuse treatment clinical trials network: Characteristics, opinions, and beliefs. Psychiatr Serv. 2007;58:181-190. (Pubitemid 46340461)
38. Rogers EM. Diffusion of Innovations. 5th ed. New York: Free Press; 1995.
39. Damanpour F. Organizational innovation: A meta-analysis of effects of determinants and moderators. Acad Manage J. 1991;34:555-590.
40. Ducharme LJ, Knudsen HK, Roman PM, et al. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat. 2007;32:321-329.
41. Mark TL, Kranzler HR, Song X, et al. Physicians- opinions about medications to treat alcoholism. Addiction. 2003;98:617-626. (Pubitemid 36638200)
42. Corrigan PW, Steiner L, McCracken SG, et al. Strategies for disseminating evidence-based practices to staff who treat people with serious mental illness. Psychiatr Serv. 2001;52:1598-1606. (Pubitemid 33104451)
43. Kellogg S, Melia D, Khuri E, et al. Adolescent and young adult heroin patients: Drug use and success in methadone maintenance treatment. J Addict Dis. 2006;25:15-25. (Pubitemid 44352899)
44. Brown BS, Flynn PM. The federal role in drug abuse technology transfer: A history and perspective. J Subst Abuse Treat. 2002;22: 245-257.
45. Mizik N, Jacobson R. Are physicians "easy marks" ? Quantifying the effects of detailing and sampling on new prescriptions. Manage Sci. 2004;50:1704-1715. (Pubitemid 40086744)
46. Mee-Lee D, Gartner L, Miller MM, et al. Patient Placement Criteria for the Treatment of Substance-Related Disorders. 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine; 1996.
47. Long JS. Regression Models for Categorical and Limited Dependent Variables. Thousand Oaks, CA: Sage; 1997.
48. Long JS, Freese J. Regression Models for Categorical Dependent Variables Using Stata. College Station, TX: StataCorp; 2003.
49. Knudsen HK, Ducharme LJ, Roman PM. Racial and ethnic disparities in SSRI availability in substance abuse treatment. Psychiatr Serv. 2007; 58:55-62.
50. Knudsen HK, Roman PM. Modeling the use of innovations in private treatment organizations: The role of absorptive capacity. J Subst Abuse Treat. 2004;26:353-361.
51. Vassilev ZP, Strauss SM, Astone JM, et al. Provision of on-site medical care to patients with hepatitis C in drug treatment units. J Health Care Poor Underserved. 2004;15:663-671.
52. Friedmann PD, Alexander JA, D-Aunno TA. Organizational correlates of access to primary care and mental health services in drug abuse treatment units. J Subst Abuse Treat. 1999;16:71-80. (Pubitemid 29021887)
53. McLellan AT, Carise D, Kleber HD. Can the national addiction treatment infrastructure support the public-s demand for quality care? J Subst Abuse Treat. 2003;25:117-121. (Pubitemid 37415291)
54. Friedmann PD, Zhang Z, Hendrickson J, et al. Effect of primary medical care on addiction and medical severity in substance abuse treatment programs. J Gen Intern Med. 2003;18:1-8. (Pubitemid 36114958)
55. Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: Patient, provider, and societal perspectives. Arch Intern Med. 2001;161:85-91. (Pubitemid 32052147)
56. Marinelli-Casey P, Domier CP, Rawson RA. The gap between research and practice in substance abuse treatment. Psychiatr Serv. 2002;53:984-987. (Pubitemid 34816091)
57. Cooper RA, Getzen TE, McKee HJ, et al. Economic and demographic trends signal an impending physician shortage. Health Aff (Millwood). 2002;21:140-154.
58. Spetz J, Given R. The future of the nurse shortage: Will wage increases close the gap? Health Aff (Millwood). 2003;22:199-206. (Pubitemid 41399234)
59. Narayanan S, Desiraju R, Chintagunta PK. Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. J Marketing. 2004;68:90-105. (Pubitemid 39508314)
60. Friedmann PD, Lemon SC, Durkin EM, et al. Trends in comprehensive service availability in outpatient drug abuse treatment. J Subst Abuse Treat. 2003;24:81-88.
61. Richter KP, Choi WS, McCool RM, et al. Smoking cessation services in U.S. methadone maintenance facilities. Psychiatr Serv. 2004;55:1258-1264.